File | Jotup

File US Trademark Simplifies Trademark Filing, Making it Easy, Convenient, and Affordable for Businesses

Retrieved on:

четверг, мая 9, 2024

Multimedia, Environment, Name, Private law, Amazon, Company formation, COVID-19, File, LOS, Rest

LOS ANGELES, May 9, 2024 /PRNewswire-PRWeb/ -- With an increasingly growing inclination of individuals, Gen Z's and post-COVID lessons, there has been a high volume of businesses, self employed individuals and novel products and services coming into inception across the world and in the US.

Key Points:

This has created a need for businesses to efficiently and affordably file for securing their brand names and businesses, be it to trademark business name, trademark company name or a service.
Businesses looking to get a trademark registered need not worry about going through documentational intricacies or long queues.
Trademark registration in the US can be pursued by an individual, or they have the option to file a trademark with the assistance of expert attorneys.
File US Trademark services also include amazon trademark registration, which is a necessary step in stepping up an Amazon Brand Registry, Company Formation and other legal services.

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

Retrieved on:

четверг, мая 9, 2024

MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update.

Key Points:

MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update.
At March 31, 2024, we had cash of $6.5 million as compared with $8.5 million at December 31, 2023.
Net loss was $2.2 million for the three months ended March 31, 2024 as compared with $3.6 million for the three months ended March 31, 2023.
The decrease in net loss was primarily due to the changes in research and development expenses, as described above.

Stockholder Alert: Robbins LLP Reminds BLUE Investors of Upcoming May 28, 2024 Lead Plaintiff Deadline in the Bluebird Bio, Inc. Class Action

Retrieved on:

четверг, мая 9, 2024

Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points:

Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What Now: You may be eligible to participate in the class action against bluebird bio, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 28, 2024.
A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Navitas Semiconductor Announces First Quarter 2024 Financial Results

Retrieved on:

четверг, мая 9, 2024

TORRANCE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation power semiconductors, today announced unaudited financial results for the first quarter ended March 31, 2024.

Key Points:

TORRANCE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation power semiconductors, today announced unaudited financial results for the first quarter ended March 31, 2024.
On a non-GAAP basis, loss from operations for the quarter was $11.8 million compared to a loss of $12.3 million for the first quarter of 2023.
Navitas Q1 2024 Financial Results Conference Call and Webcast Information:
Toll Free Dial-in: (800) 715-9871 or (646) 307-1963, Conference ID: 4587273
Our quarterly report on Form 10-Q for the period ended March 31, 2024 is due to be filed with the SEC on May 10, 2024.
Each of these non-GAAP financial measures are adjusted from GAAP results to exclude certain expenses which are outlined in the “Reconciliation of GAAP Results to Non-GAAP Financial Measures” tables below.

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

Retrieved on:

четверг, мая 9, 2024

8-K, Security (finance), OTCQX, File

MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and to suspend its reporting obligations under Section 15(d) of the Exchange Act.

Key Points:

MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and to suspend its reporting obligations under Section 15(d) of the Exchange Act.
The Company’s obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15.
Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Company will no longer be a public reporting company and its obligations to file other reports with the SEC will also be suspended.

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Retrieved on:

четверг, мая 9, 2024

LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points:

MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
As of March 31, 2024, MeiraGTx had cash and cash equivalents of approximately $119.2 million and in April 2024, the Company collected $19.7 million in receivables which were due in the first quarter of 2024, effectively increasing the cash balance to $138.9 million.
The increase of $0.6 million was due to higher interest rates and cash balances during 2024.
Interest expense was $3.3 million for the three months ended March 31, 2024, compared to $3.1 million for the three months ended March 31, 2023.

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

Retrieved on:

четверг, мая 9, 2024

FDA, International, NDA, Security (finance), Netherton syndrome, File, Pharmaceutical industry

ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the first quarter ended March 31, 2024.

Key Points:

ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the first quarter ended March 31, 2024.
Quoin CEO, Dr. Michael Myers, said, “We are pleased to announce this encouraging start to 2024 as throughout the past quarter we successfully built upon the positive momentum from last year.
Quoin had approximately $14.7 million in cash, cash equivalents and marketable securities as of March 31, 2024.
Net loss for the quarter ended March 31, 2024 was approximately $2.3 million compared to approximately $2.6 million for the quarter ended March 31, 2023.

RxSight, Inc. Announces Pricing of Public Offering of Common Stock

Retrieved on:

четверг, мая 9, 2024

Sale, Prospectus, Broadridge Financial Solutions, Security (finance), Research, Form S-3, J. P. Morgan, Form, Patient, Marketing, BofA Securities, Attention, Telephone, File

RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share.

Key Points:

RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share.
RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions.
RxSight filed a preliminary prospectus supplement and accompanying prospectus relating to the offering with the SEC on May 8, 2024.
The offering may be made only by means of a prospectus supplement and accompanying prospectus.

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on:

четверг, мая 9, 2024

“The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points:

“The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
“We are driven by our commitment to provide patients with the broadest gMG product offering that consistently delivers on safety and efficacy.
VYVGART SC played a key role in our growth over the quarter, expanding the breadth of our prescriber base and reaching new patients.
In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

RxSight, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on:

среда, мая 8, 2024

Sale, Prospectus, Broadridge Financial Solutions, Security (finance), Research, Form S-3, J. P. Morgan, Form, Patient, Marketing, BofA Securities, Attention, Telephone, File

In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions.

Key Points:

In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions.
There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
An automatic shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on May 8, 2024, which became automatically effective upon filing.
The proposed offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement.